Mark Eccleston
Dr Mark Eccleston is polymer chemist and biotechnology entrepreneur with over 30 years experience working in translation science in both drug and biomarker development. Mark is a former BBSRC Enterprise fellow and holds an MBA (Entrepreneurship).
He is an inventor on over 30 patents ranging from peptide and CAR-T cell therapies to nucleosome enrichment as well as biodegradable chewing gum.
Mark is the CEO of ValiRx Plc, an AIM listed UK pharmaceutical development company whose focus is progressing early-stage assets through the value chain. He is a scientific founder of several companies, including Volition, where he currently serves on the Scientific Advisory Board. He is also CEO of OncoLytika Ltd. A biotech consultancy company established in 2010.
In addition to his commercial activities, Mark has supervised multiple PhD and Masters students at various universities, including the Open University, Greenwich University and DKFZ in Germany. He also serves as an external advisor to the Open University, contributing to modules focused on employability of biosciences graduates and employer expectations from graduates in terms of bioinformatics training.
He is an inventor on over 30 patents ranging from peptide and CAR-T cell therapies to nucleosome enrichment as well as biodegradable chewing gum.
Mark is the CEO of ValiRx Plc, an AIM listed UK pharmaceutical development company whose focus is progressing early-stage assets through the value chain. He is a scientific founder of several companies, including Volition, where he currently serves on the Scientific Advisory Board. He is also CEO of OncoLytika Ltd. A biotech consultancy company established in 2010.
In addition to his commercial activities, Mark has supervised multiple PhD and Masters students at various universities, including the Open University, Greenwich University and DKFZ in Germany. He also serves as an external advisor to the Open University, contributing to modules focused on employability of biosciences graduates and employer expectations from graduates in terms of bioinformatics training.